Published in Can J Gastroenterol Hepatol on September 01, 2014
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis (2015) 1.22
Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94
Unemployment, health, and education of HIV-infected males in Germany. Int J Public Health (2015) 0.80
pH-dependent conformational changes in the HCV NS3 protein modulate its ATPase and helicase activities. PLoS One (2014) 0.79
Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evol (2016) 0.78
Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol (2015) 0.76
Hepatitis C: New challenges in liver transplantation. World J Gastroenterol (2015) 0.76
Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. Int J Clin Exp Med (2015) 0.76
Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen. ACG Case Rep J (2017) 0.75
With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs? Can J Gastroenterol Hepatol (2014) 0.75
Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepat Res Treat (2016) 0.75
Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs. Bioorg Med Chem Lett (2017) 0.75
Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence. Dig Dis Sci (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol (2013) 2.87
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology (2013) 1.88
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology (2013) 1.84
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology (2013) 1.78
HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int (2014) 1.62
Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol (2012) 1.50
Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med (2014) 1.50
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol (2013) 1.47
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother (2010) 1.42
Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol (2013) 1.21
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol (2013) 1.12
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2013) 1.11
Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant (2003) 1.04
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol (2013) 1.00
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology (2014) 0.98
Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician (2005) 0.83
Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology (2011) 0.80
Hepatitis C virus infection: looking for interferon free regimens. ScientificWorldJournal (2013) 0.77
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg (2009) 1.91
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
Exploring the psychological effects of deceased organ donation on the families of the organ donors. Clin Transplant (2008) 1.75
Granulomatous hepatitis associated with etanercept therapy. J Rheumatol (2008) 1.56
Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth (2005) 1.55
Pregnancy and sexual function in liver transplantation. J Hepatol (2008) 1.49
Cross-sectional study of hepatitis B awareness among Chinese and Southeast Asian Canadians in the Vancouver-Richmond community. Can J Gastroenterol (2005) 1.47
Spatulated end-to-end bile duct reconstruction in orthotopic liver transplantation. Clin Transplant (2007) 1.39
Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol (2009) 1.22
Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma (2005) 1.21
Choledochal cysts. Part 3 of 3: management. Can J Surg (2010) 1.21
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19
Gastric polyps in patients with portal hypertension. Eur J Gastroenterol Hepatol (2011) 1.16
Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol (2013) 1.15
Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol (2010) 1.14
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13
Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol (2009) 1.10
Does this patient with liver disease have cirrhosis? JAMA (2012) 1.09
Safety and efficacy of Hemospray® in upper gastrointestinal bleeding. Can J Gastroenterol Hepatol (2014) 1.05
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol (2012) 1.05
Choledochal cysts: part 2 of 3: Diagnosis. Can J Surg (2009) 1.03
Acute fatty liver of pregnancy. Can J Gastroenterol (2006) 1.03
Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl (2002) 1.01
Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review. Ann Hepatol (2012) 0.99
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol (2010) 0.94
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol (2005) 0.93
Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig Dis Sci (2002) 0.93
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol (2012) 0.91
Late acute celiac and hepatic artery thrombosis with portal vein thrombosis resulting in hepatic infarction 12 years post orthotopic liver transplantation. Ann Hepatol (2009) 0.91
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90
Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol (2005) 0.89
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy (2008) 0.89
Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol (2009) 0.88
Effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients after transplantation. Am J Cardiol (2004) 0.87
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol (2006) 0.87
Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol (2003) 0.87
Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. Ann Hepatol (2010) 0.86
Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol (2007) 0.86
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol (2006) 0.85
Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85
Transient improvement of acquired hepatocerebral degeneration with parkinsonian symptoms after failed liver transplant: case report and literature review. Exp Clin Transplant (2011) 0.85
Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int (2009) 0.84
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can J Gastroenterol (2013) 0.83
Ethnic variation in the annual rates of adult inflammatory bowel disease in hospitalized patients in Vancouver, British Columbia. Can J Gastroenterol (2011) 0.83
First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol (2013) 0.83
Response to endoscopic therapy for biliary anastomotic strictures in deceased versus living donor liver transplantation. Hepatobiliary Pancreat Dis Int (2013) 0.83
Recurrent ectopic pancreatitis of the jejunum and mesentery over a 30-year period. Hepatobiliary Pancreat Dis Int (2011) 0.82
Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. Transplantation (2006) 0.82
Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol (2006) 0.82
Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation (2006) 0.81
Carnitine deficiency presenting with encephalopathy and hyperammonemia in a patient receiving chronic enteral tube feeding: a case report. J Med Case Rep (2012) 0.81
A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. Cases J (2009) 0.81
Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol (2007) 0.81
Sexual health after orthotopic liver transplantation. Liver Transpl (2006) 0.81
Abdominal pain as the initial and sole clinical presenting feature of systemic lupus erythematosus. Can J Gastroenterol (2003) 0.81
The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation. Ann Hepatol (2009) 0.80
The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol (2008) 0.80
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor. Antivir Ther (2014) 0.80
Surgical morbidity in severely obese liver transplant recipients - a single Canadian Centre Experience. Ann Hepatol (2009) 0.80
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience. Transplantation (2016) 0.79
Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res (2008) 0.79
Familial adenomatous polyposis-rendering a diagnosis based on recognition of an unusual primary thyroid neoplasm. Case Rep Med (2011) 0.79
Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant (2006) 0.79
Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital. Can J Gastroenterol Hepatol (2014) 0.79
Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol (2010) 0.79
Liver transplantation for alcoholic liver disease among Canadian transplant centres: a national study. Can J Gastroenterol (2013) 0.78
Treatment issues surrounding hepatitis C in renal transplantation: a review. Ann Hepatol (2011) 0.78
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int (2009) 0.78
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother (2007) 0.78
Racial differences between solid organ transplant donors and recipients in British Columbia 2005-2009: a follow-up study since the last analysis in 1993-1997. Transplantation (2013) 0.78
Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Ann Hepatol (2009) 0.78
Patient time costs and out-of-pocket costs in hepatitis C. Liver Int (2012) 0.78
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol (2008) 0.78
Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study. Ann Hepatol (2013) 0.78
The prevalence of gestational diabetes mellitus and glucose abnormalities in pregnant women with hepatitis C virus infection in British Columbia. J Obstet Gynaecol Can (2010) 0.77
Echinococcus presenting as painless jaundice. Can J Gastroenterol (2012) 0.77
Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Exp Clin Transplant (2016) 0.77
Assessing medication adherence in solid-organ transplant recipients. Exp Clin Transplant (2013) 0.77
Hepatitis C infection among pregnant women in British Columbia: reported prevalence and critical appraisal of current prenatal screening methods. Can J Public Health (2011) 0.77
Adult live donor liver transplantation: routine, commonplace, standard care for end stage liver disease (we hope). Ann Hepatol (2010) 0.76
Recurrent idiopathic acute hepatitis-associated aplastic anemia/pancytopenia fourteen years after initial episode. Ann Hepatol (2010) 0.76
Acetylcholine receptor antibody positive generalized myasthenia gravis in association with primary biliary cirrhosis. Ann Hepatol (2010) 0.76
Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res (2006) 0.76
Methadone maintenance therapy in liver transplantation. Prog Transplant (2010) 0.76
Acute Budd-Chiari syndrome. Can J Gastroenterol (2011) 0.76
A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol (2011) 0.76